Association between NFKB1 −94ins/del ATTG Promoter Polymorphism and Cancer Susceptibility: An Updated Meta-Analysis

Table 2

Meta-analysis of the NFKB1 −94ins/del ATTG promoter polymorphism and cancer risk.

Variables

𝑛^a

Cases/Controls

ins/ins versus del/del

ins/del versus del/del

ins/ins + ins/del versus del/del (dominant)

ins/ins versus ins/del + del/del (recessive)

ins allele versus del allele

OR; (95% CI)

𝐼^2 (%)

OR; (95% CI)

𝐼^2 (%)

OR; (95% CI)

𝐼^2 (%)

OR; (95% CI)

𝐼^2 (%)

OR (95% CI)

𝐼^2 (%)

Total

21

6127/9239

1.47 (1.11–1.93) ^b

84.8

1.15 (0.97–1.37)^b

67.7

1.26 (1.03–1.53) ^b

77.5

1.26 (1.05–1.51) ^b

82.3

1.19 (1.05–1.35) ^b

84.0

Cancer types

Bladder cancer

3

1058/1175

1.07 (0.45–2.53)^b

90.1

1.00 (0.46–2.18)^b

88.8

1.04; (0.46–2.33)^b

90.7

1.04 (0.73–1.48)^b

72.7

1.03 (0.70–1.51)^b

89.0

Colorectal cancer

4

1275/1890

0.84 (0.47–1.50)^b

82.9

0.93 (0.77–1.13)

0

0.88; (0.73–1.06)

0

0.89 (0.51–1.55)^b

88.9

0.90; (0.72–1.12)^b

76.2

Ovarian cancer

2

366/444

2.57 (1.66–3.98)

0

1.88 (1.23–2.89)

0

2.17 (1.45–3.25)

0

1.59 (1.19–2.11)

0

1.55 (1.27–1.90)

0

Oral cancer

2

674/721

2.10 (1.54–2.87)

33.0

1.42 (1.10–1.83)

0

1.59 (1.25–2.03)

3.9

1.67 (1.29–2.17)

0

1.43 (1.23–1.66)

6.9

Prostate cancer

2

451/477

1.59 (1.09–2.33)

23.0

1.28 (0.89–1.84)

28.6

1.40 (1.00–1.98)

35.8

1.33 (1.01–1.74)

0

1.26 (1.05–1.52)

0

Other cancers

8

2303/4532

1.72 (1.13–2.61) ^b

80.9

1.16 (0.88–1.53)^b

61.3

1.34 (0.99–1.83) ^b

72.4

1.46 (1.12–1.90) ^b

78.0

1.29 (1.07–1.57) ^b

79.9

Ethnicities

Asian

14

4143/5169

1.83 (1.30–2.57) ^b

84.8

1.23 (0.97–1.58)^b

75.9

1.42 (1.08–1.86) ^b

82.5

1.50 (1.26–1.78) ^b

66.8

1.32 (1.14–1.54) ^b

82.2

Caucasian

7

1984/4070

0.90 (0.64–1.27)^b

71.2

1.00 (0.85–1.18)

18.5

0.95 (0.81–1.10)

24.0

0.90 (0.66–1.23)^b

83.7

0.95 (0.82–1.12)^b

70.9

aNumber of comparisons.
^bRandom effects estimate.